Miscellaneous: Neuroendocrine tumour: WHO grading
Free question published 05 November 2026
A 55-year-old woman has a resected well-differentiated pancreatic neuroendocrine tumour. The histopathology report states a mitotic count of 3 per 2 mm squared and a Ki-67 proliferation index of 12%. Using the WHO 2019 classification of gastroenteropancreatic neuroendocrine neoplasms, how should this tumour be graded?
- AGrade 1 well-differentiated neuroendocrine tumour
- BPoorly differentiated neuroendocrine carcinoma
- CMixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN)
- DGrade 2 well-differentiated neuroendocrine tumour
- EGrade 3 well-differentiated neuroendocrine tumour
Why D is correct
In the WHO 2019 classification, well-differentiated neuroendocrine tumours are graded by Ki-67 index and mitotic rate: grade 1 (Ki-67 under 3% and under 2 mitoses per 2 mm squared), grade 2 (Ki-67 3 to 20% or 2 to 20 mitoses per 2 mm squared) and grade 3 (Ki-67 over 20% or over 20 mitoses per 2 mm squared). Here both the Ki-67 of 12% and the mitotic count of 3 per 2 mm squared fall in the grade 2 band, so this is a grade 2 well-differentiated NET. The key learning point is that morphological well-differentiation with a Ki-67 of 12% defines grade 2, distinguishing it from a poorly differentiated NEC despite the raised proliferation index.
And why the others are not
- AGrade 1 requires Ki-67 under 3% and mitoses under 2 per 2 mm squared; this tumour exceeds both.
- BPoorly differentiated NEC is defined by poor morphological differentiation, not by a Ki-67 of 12% in a well-differentiated tumour.
- CMiNEN requires a mixed neuroendocrine and non-neuroendocrine component, which is not described here.
- EGrade 3 well-differentiated NET requires Ki-67 over 20%; a Ki-67 of 12% does not meet this threshold.
Source WHO 2019 classification and grading of gastroenteropancreatic neuroendocrine neoplasms — Nagtegaal ID, Odze RD, Klimstra D, et al (WHO Classification of Tumours Editorial Board). The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188.
More free miscellaneous questions
- Miscellaneous: Bone sarcoma: osteosarcoma chemotherapy · 25 October 2026
- Miscellaneous: CUP: favourable subset (peritoneal) · 16 November 2026
- Miscellaneous: Bone sarcoma: Ewing chemotherapy (Euro Ewing 2012) · 14 October 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing